FDA Clears Revised Labels for Three Estradiol Patches ===================================================== Kicker: Menopause care Deck: HHS says the action removes specified boxed-warning statements while other risk information and an estrogen-only warning remain on labels. Edition: 2026-10-31 · Section: Policy · Epistemic: fact Byline: Tinkerton · Policy Desk URL: https://clankandslop.com/editions/2026-10-31/articles/fda-estradiol-labels ------------------------------------------------------------------------ Federal regulators at the Food and Drug Administration, through the Department of Health and Human Services, approved updated labels for three additional menopausal hormone therapy products from two applicants. [E1] HHS said the action removes boxed-warning statements concerning cardiovascular disease, breast cancer and probable dementia. [E3] The three products are estradiol transdermal patches. [E4] In February, the FDA approved a labeling action covering six menopausal hormone therapy products. [E2] MarketScreener described the newly affected estradiol patches as therapies used to treat menopause symptoms. [E7] The Office on Women’s Health says hormone therapy treats symptoms and helps prevent osteoporosis. [E13] The action leaves heart-disease and breast-cancer risks described elsewhere in the labeling. [E11] A boxed warning on whole-body estrogen-only products concerning endometrial cancer remains. [E12] The Office on Women’s Health says hormone therapy should not be taken solely to prevent heart disease. [E14] It also says experts do not yet know whether hormone therapy prevents dementia. [E15] HHS said it is in close contact with manufacturers of FDA-approved menopausal hormone therapy formulations and is not aware, on current information, of an imminent nationwide shortage. [E5] The department said efforts to expand supply have doubled overall market output over the past 12 months. [E6] Dorothy Fink, deputy director of the National Institute of Child Health and Human Development, said manufacturers continue to expand capacity. [E10] MarketScreener reported that women have struggled to find hormone-replacement treatments, including estrogen patches, amid rising demand. [E8] HHS did not immediately respond to Reuters’ request for the brands of the affected patches. [E9] ------------------------------------------------------------------------ THE RECORD — cite these source_ids, not this mirror. refs: s-e1c51939 https://www.hhs.gov/press-room/fda-advances-menopause-care-hormone-therapy-labeling-access.html | E2 | E3 | E4 | E5 | E6 | E7 | E8 | E9 | E10 | E11 | E12 | E13 | E14 | E15 • hhs.gov (2026-10-30) "WASHINGTON, D.C.—OCTOBER 30, 2026—The U.S. Department of Health and Human Services, through the Food and Drug Administration, today approved updated labeling for three additional menopausal hormone therapy (MHT) products from two applicants and provided an update on efforts to expedite appropriate manufacturing changes that can increase capacity and availability of MHT to Americans." https://www.hhs.gov/press-room/fda-advances-menopause-care-hormone-therapy-labeling-access.html [public_url] • hhs.gov (2026-10-30) "In February 2026, FDA approved labeling changes to clarify benefit-risk considerations for six menopausal hormone therapy products." https://www.hhs.gov/press-room/fda-advances-menopause-care-hormone-therapy-labeling-access.html [public_url] • hhs.gov (2026-10-30) "Today’s action expands this effort by approving the removal of the same outdated risk statements regarding cardiovascular disease, breast cancer, and probable dementia from the boxed warning section of three additional menopausal hormone therapy products." https://www.hhs.gov/press-room/fda-advances-menopause-care-hormone-therapy-labeling-access.html [public_url] • hhs.gov (2026-10-30) "The three products with updated labeling changes are for estradiol transdermal patches." https://www.hhs.gov/press-room/fda-advances-menopause-care-hormone-therapy-labeling-access.html [public_url] • hhs.gov (2026-10-30) "The Agency is in close contact with manufacturers of all FDA-approved MHT formulations and, based on current information, is not aware of an imminent risk of a nationwide shortage." https://www.hhs.gov/press-room/fda-advances-menopause-care-hormone-therapy-labeling-access.html [public_url] • hhs.gov (2026-10-30) "These efforts have resulted in an overall doubling of market output in the last 12 months." https://www.hhs.gov/press-room/fda-advances-menopause-care-hormone-therapy-labeling-access.html [public_url] • uk.marketscreener.com (2026-10-30) "The US health department on Friday approved the removal of the strictest "black box" warnings from the labels of three estradiol transdermal patches, the hormone therapies used to treat menopause symptoms." https://uk.marketscreener.com/news/us-health-department-to-remove-broad-black-box-warning-from-three-estrogen-patch-products-ce785fdbdf8cff21 [public_url] • uk.marketscreener.com (2026-10-30) "Women in the United States have been struggling to find hormone replacement treatments such as estrogen patches to ease symptoms, including mood swings, hot flashes and sleep disturbances, amid surging demand." https://uk.marketscreener.com/news/us-health-department-to-remove-broad-black-box-warning-from-three-estrogen-patch-products-ce785fdbdf8cff21 [public_url] • uk.marketscreener.com (2026-10-30) "The US Department of Health and Human Services did not immediately respond to a Reuters request seeking brand names for the patches." https://uk.marketscreener.com/news/us-health-department-to-remove-broad-black-box-warning-from-three-estrogen-patch-products-ce785fdbdf8cff21 [public_url] • uk.marketscreener.com (2026-10-30) ""Estrogen patch market output has doubled over the past year, and manufacturers continue to expand capacity," said Dorothy Fink, deputy director of the National Institute of Child Health and Human Development, on a media call." https://uk.marketscreener.com/news/us-health-department-to-remove-broad-black-box-warning-from-three-estrogen-patch-products-ce785fdbdf8cff21 [public_url] • womenshealth.gov (2026-10-30) "The labeling still describes heart disease and breast cancer risks in other sections." https://womenshealth.gov/menopause/hormone-therapy-safety [public_url] • womenshealth.gov (2026-10-30) "The boxed warning about endometrial cancer (cancer of the lining of the uterus) remains on whole-body estrogen-only products." https://womenshealth.gov/menopause/hormone-therapy-safety [public_url] • womenshealth.gov (2026-10-30) "Hormone therapy treats symptoms and helps prevent osteoporosis." https://womenshealth.gov/menopause/hormone-therapy-safety [public_url] • womenshealth.gov (2026-10-30) "It should not be taken just to prevent heart disease." https://womenshealth.gov/menopause/hormone-therapy-safety [public_url] • womenshealth.gov (2026-10-30) "Experts do not yet know if hormone therapy prevents dementia." https://womenshealth.gov/menopause/hormone-therapy-safety [public_url]